Given the broader anti-leukemic effects associated with this pathway, the identification of novel PI3K/Akt/mTOR inhibitors and exploration of underlying mechanisms would greatly benefit to the translation to clinically optimized strategies for AML treatment. Here, AKT1 is linked to acute myeloid leukemia.